Thrombosis Research
Volume 122 , Pages S9-S15 , 2008

Pre-clinical studies of plasmin: Superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported by Grant RO1 HL 074051 from the National Heart Lung and Blood Institute, NIH, Bethesda, MD, and by a grant from Talecris BioTherapeutics, RTP, NC.

PII: S0049-3848(08)00239-9

doi: 10.1016/j.thromres.2008.06.019

Thrombosis Research
Volume 122 , Pages S9-S15 , 2008

Article Tools

* Image Usage & Resolution